Anaptysbio (ANAB) Amortization of Deferred Charges (2020 - 2026)
Anaptysbio (ANAB) posted Amortization of Deferred Charges of $480000.0 for Q1 2026, up 1.05% on a QoQ basis from $475000.0 in Q4 2025, and up 4.35% year-over-year from $460000.0 in Q1 2025.
Anaptysbio (ANAB) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Anaptysbio's Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $480000.0 for Q1 2026.
- Quarterly Amortization of Deferred Charges rose 4.35% year-over-year to $480000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 4.15% YoY) and the FY2025 annual result came in at $1.9 million, up 4.08% from the prior year.
- Amortization of Deferred Charges was $480000.0 for Q1 2026 at Anaptysbio, up from $475000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $480000.0 in Q1 2026 and bottomed at $408000.0 in Q2 2022.
- A 5-year average of $442294.1 and a median of $441000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Peak annual rise in Amortization of Deferred Charges reached 226.19% in 2022, while the deepest fall reached 34.72% in 2022.
- Anaptysbio's Amortization of Deferred Charges stood at $422000.0 in 2022, then gained by 4.03% to $439000.0 in 2023, then increased by 3.87% to $456000.0 in 2024, then increased by 4.17% to $475000.0 in 2025, then gained by 1.05% to $480000.0 in 2026.
- Business Quant data shows ANAB's Amortization of Deferred Charges at $480000.0 in Q1 2026, $475000.0 in Q4 2025, and $470000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Anaptysbio | 1.58 Bn | 1.29 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 480,000.00 |
| Mar 31, 2026 | 480,000.00 |
| Dec 31, 2025 | 475,000.00 |
| Dec 31, 2025 | 475,000.00 |
| Sep 30, 2025 | 470,000.00 |
| Sep 30, 2025 | 470,000.00 |
| Jun 30, 2025 | 459,000.00 |
| Jun 30, 2025 | 459,000.00 |
| Mar 31, 2025 | 460,000.00 |
| Mar 31, 2025 | 460,000.00 |
| Dec 31, 2024 | 456,000.00 |
| Dec 31, 2024 | 456,000.00 |
| Sep 30, 2024 | 452,000.00 |
| Sep 30, 2024 | 452,000.00 |
| Jun 30, 2024 | 441,000.00 |
| Jun 30, 2024 | 441,000.00 |
| Mar 31, 2024 | 442,000.00 |
| Mar 31, 2024 | 442,000.00 |
| Dec 31, 2023 | 439,000.00 |
| Dec 31, 2023 | 439,000.00 |